Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05872620 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,613
- Enrollment target
- 20
- Study locations
NCT05872620: Completed Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
NCT05872620 is a Phase 3 study of Obesity and Type 2 Diabetes that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,613 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05872620, a Phase 3 study of Obesity and Type 2 Diabetes, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,613 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Primary Outcome
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral antihyperglycemic medications (AHMs) classified according to their potential effect on body weight (promoting weight gain,
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
California
- AMCR Institute - Escondido
- Velocity Clinical Research, Huntington Park - Huntington Park
- Velocity Clinical Research, Westlake - Los Angeles
- Catalina Research Institute, LLC - Montclair
- University Clinical Investigators, Inc. - Tustin
Florida
- Encore Medical Research - Hollywood
- East Coast Institute for Research, LLC - Jacksonville
- South Florida Clinical Research Institute - Margate
- Suncoast Clinical Research, Inc. - New Port Richey
Georgia
- Balanced Life Health Care Solutions/SKYCRNG - Lawrenceville
- Endocrine Research Solutions, Inc. - Roswell
- North Georgia Clinical Research - Woodstock
Arizona
- Novak Clinical Research - Tucson - North La Cholla Boulevard - Tucson
- Yuma Clinical Trials - Yuma
Alabama
- Cahaba Research - Pelham - Pelham
Hawaii
- Pacific Diabetes & Endocrine Center - Honolulu
Idaho
- Solaris Clinical Research - Meridian
Iowa
- Iowa Diabetes and Endocrinology Research Center - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,613 participants |
| Start Date | 2023-06-05 |
| Est. Completion | 2025-08-08 |
| Phase | Phase 3 |
What the finished NCT05872620 record still lists
NCT05872620 is an interventional study that assigns participants to a tested intervention. Its 1,613 participants enrollment target places it among the larger protocols in the corpus, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (97% higher).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05872620 names 20 study sites across 10 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05872620 about?
NCT05872620 is a clinical study titled "A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes". This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
What is the current status of trial NCT05872620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,613 participants. The study started on 2023-06-05. Estimated completion is 2025-08-08.
What conditions does trial NCT05872620 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight.
What interventions are being tested in trial NCT05872620?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT05872620?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05872620 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05872620's enrollment target sits among peer trials
1,613 54th of 1053 higher than 1,000 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06959524 · 1,616 participants · NA
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- NCT06271590 · 1,605 participants · NA
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI